Shares of Dynavax Technologies Corp. soared 45.7 percent Thursday after the FDA lifted a clinical hold on the company's investigational hepatitis B vaccine Heplisav, an immunostimulatory sequence targeting Toll-like receptor 9 (TLR9) combined with hepatitis B surface antigen, finally giving the biotech some good news after 18 months of tribulations. (BioWorld Today)